2023 Multidisciplinary Thoracic Oncology Conference (MTOC) - VAMC Evaluation

1 Start 2 Complete

Overall Objectives *

Please rate how well the overall learning objectives for 2023 Multidisciplinary Thoracic Oncology Conference (MTOC) - VAMC were met.

	Poor	Fair	Average	Good	Excellent
Improve early detection of lung cancer and management of lung nodules by implementing new radiology guidelines, non-invasive proteomic/genomic serological testing, and artificial intelligence / machine learning advancements to help clinicians differentiate between potentially malignant versus benign lesions.	Improve early detection of lung cancer and management of lung nodules by implementing new radiology guidelines, non-invasive proteomic/genomic serological testing, and artificial intelligence / machine learning advancements to help clinicians differentiate between potentially malignant versus benign lesions. - Poor	Improve early detection of lung cancer and management of lung nodules by implementing new radiology guidelines, non-invasive proteomic/genomic serological testing, and artificial intelligence / machine learning advancements to help clinicians differentiate between potentially malignant versus benign lesions. - Fair	Improve early detection of lung cancer and management of lung nodules by implementing new radiology guidelines, non-invasive proteomic/genomic serological testing, and artificial intelligence / machine learning advancements to help clinicians differentiate between potentially malignant versus benign lesions. - Average	Improve early detection of lung cancer and management of lung nodules by implementing new radiology guidelines, non-invasive proteomic/genomic serological testing, and artificial intelligence / machine learning advancements to help clinicians differentiate between potentially malignant versus benign lesions. - Good	Improve early detection of lung cancer and management of lung nodules by implementing new radiology guidelines, non-invasive proteomic/genomic serological testing, and artificial intelligence / machine learning advancements to help clinicians differentiate between potentially malignant versus benign lesions. - Excellent
Provide state-of-the-art diagnostic procedures and teaching residents, fellows, and attendings to identify appropriate candidates for the best, most effective procedures.	Provide state-of-the-art diagnostic procedures and teaching residents, fellows, and attendings to identify appropriate candidates for the best, most effective procedures. - Poor	Provide state-of-the-art diagnostic procedures and teaching residents, fellows, and attendings to identify appropriate candidates for the best, most effective procedures. - Fair	Provide state-of-the-art diagnostic procedures and teaching residents, fellows, and attendings to identify appropriate candidates for the best, most effective procedures. - Average	Provide state-of-the-art diagnostic procedures and teaching residents, fellows, and attendings to identify appropriate candidates for the best, most effective procedures. - Good	Provide state-of-the-art diagnostic procedures and teaching residents, fellows, and attendings to identify appropriate candidates for the best, most effective procedures. - Excellent
Formulate advanced, patient centric treatment plans for early-stage cancers with curative intent, introducing molecular testing in the treatment pathways, and assessing the appropriateness for neoadjuvant and adjuvant chemotherapy, immunotherapy, radiation therapy, and/or surgery.	Formulate advanced, patient centric treatment plans for early-stage cancers with curative intent, introducing molecular testing in the treatment pathways, and assessing the appropriateness for neoadjuvant and adjuvant chemotherapy, immunotherapy, radiation therapy, and/or surgery. - Poor	Formulate advanced, patient centric treatment plans for early-stage cancers with curative intent, introducing molecular testing in the treatment pathways, and assessing the appropriateness for neoadjuvant and adjuvant chemotherapy, immunotherapy, radiation therapy, and/or surgery. - Fair	Formulate advanced, patient centric treatment plans for early-stage cancers with curative intent, introducing molecular testing in the treatment pathways, and assessing the appropriateness for neoadjuvant and adjuvant chemotherapy, immunotherapy, radiation therapy, and/or surgery. - Average	Formulate advanced, patient centric treatment plans for early-stage cancers with curative intent, introducing molecular testing in the treatment pathways, and assessing the appropriateness for neoadjuvant and adjuvant chemotherapy, immunotherapy, radiation therapy, and/or surgery. - Good	Formulate advanced, patient centric treatment plans for early-stage cancers with curative intent, introducing molecular testing in the treatment pathways, and assessing the appropriateness for neoadjuvant and adjuvant chemotherapy, immunotherapy, radiation therapy, and/or surgery. - Excellent

What are your key takeaways? *

Will you make a change in your practice? *

Yes

What changes do you plan to make? *

What are some relevant challenges that you face in your practice? *

Lack of time

Lack of administrative support/resources

Insurance/reimbursement issues

Patient adherence issues

Lack of consensus on professional guidelines

Cost

Lack of accessible venue to gather new information

No perceived challenges

Other...

What are some relevant challenges that you face in your practice? Other...

Was the material presented in a manner that was free from commercial bias? *

Yes

No - Please describe -

Was the material presented in a manner that was free from commercial bias? No - Please describe -

Additional Comments/Suggestions?

Leave this field blank

You are here

2023 Multidisciplinary Thoracic Oncology Conference (MTOC) - VAMC Evaluation